Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15176 - 15200 of 15446 in total
Tyramine (4-hydroxyphenethylamine; para-tyramine, mydrial or uteramin) is a naturally occurring monoamine compound and trace amine derived from the amino acid tyrosine. Tyramine acts by inducing the release of catecholamine. An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only...
Investigational
Nutraceutical
Matched Description: … hydroxyphenethylamine; para-tyramine, mydrial or uteramin) is a naturally occurring monoamine compound and
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
UK-390,957 has been used in trials studying the treatment of Ejaculation.
Investigational
BMS-903452 has been used in trials studying the treatment of Diabetes.
Investigational
Dapaconazole has been used in trials studying the treatment of Tinea Pedis.
Investigational
Dalcetrapib is under investigation for the treatment of Acute Coronary Syndrome.
Investigational
LY2886721 has been used in trials studying the basic science of Alzheimer's Disease.
Investigational
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.
Investigational
E6005 has been used in trials studying the treatment of Atopic Dermatitis.
Investigational
TBD has been used in trials studying the treatment of Adenocarcinoma.
Investigational
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria. MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing...
Investigational
Matched Description: … MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against …
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
Displaying drugs 15176 - 15200 of 15446 in total